{"id":"cdfr0612","safety":{"commonSideEffects":[{"rate":"0.1-1.0%","effect":"Increased risk of diabetic ketoacidosis"},{"rate":"1.0-5.0%","effect":"Increased risk of genital yeast infections"},{"rate":"1.0-5.0%","effect":"Increased risk of hypotension"},{"rate":"0.1-1.0%","effect":"Increased risk of acute kidney injury"},{"rate":"5.0-10.0%","effect":"Increased risk of increased urination"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By inhibiting SGLT2, CDFR0612 reduces glucose reabsorption in the kidneys, leading to decreased blood glucose levels. This mechanism is particularly beneficial for patients with type 2 diabetes. CDFR0612's SGLT2 inhibition also has a secondary effect of reducing sodium reabsorption, which may contribute to its cardiovascular benefits.","oneSentence":"CDFR0612 is a small molecule that targets the SGLT2 receptor.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:05:03.485Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes"},{"name":"Cardiovascular risk reduction in patients with type 2 diabetes"}]},"trialDetails":[{"nctId":"NCT02304523","phase":"PHASE3","title":"Safety and Efficacy of CDFR0612 and CDFR0613 for Bowel Cleansing Before Colonoscopy","status":"COMPLETED","sponsor":"CTC Bio, Inc.","startDate":"2015-01","conditions":"Colonoscopy Preparation, Colon Disease","enrollment":310}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"CDFR0612","genericName":"CDFR0612","companyName":"CTC Bio, Inc.","companyId":"ctc-bio-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"CDFR0612 is a small molecule that targets the SGLT2 receptor. Used for Type 2 diabetes, Cardiovascular risk reduction in patients with type 2 diabetes.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}